The trial is taking place at:

Chattanooga Medical Research LLC. | Chattanooga, TN

Veeva-enabled site

A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Ironwood Pharmaceuticals logo

Ironwood Pharmaceuticals

Status and phase

Phase 2


Interstitial Cystitis
Bladder Pain Syndrome


Drug: Placebo
Drug: IW-3300 rectal foam

Study type


Funder types




Details and patient eligibility


The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The main question the study aims to answer is whether IW-3300 helps bladder pain and other symptoms (for example, bladder burning, pressure and discomfort). Subjects will be assigned to receive either the study drug or placebo by chance.

Full description

This is a Phase 2, randomized, placebo-controlled, parallel-assignment, 12-week, adaptive design study to evaluate the efficacy, safety, and tolerability of IW-3300 in subjects with IC/BPS. Subjects will be randomized 1:1:1 to IW-3300 100 µg, IW-3300 300 µg, or matching placebo administered as a rectal foam. The study has 4 periods, which are the screening (up to 30 days), pretreatment (up to 21 days), study treatment (12 weeks), and follow-up periods (2 weeks) which consists of 7 onsite study visits and 1 follow-up phone call. Subjects will administer the study drug at home for 12 weeks.


300 estimated patients




18 to 75 years old


No Healthy Volunteers

Inclusion criteria

  • Diagnosed with IC/BPS by a urologist or other clinician specializing in IC/BPS
  • Chronic bladder pain associated with filling the bladder over the past 6 months
  • Compliant with eDiary completion and meets weekly average daily score for bladder pain at its worst during the pretreatment period
  • Has at least 1 of the following urinary symptoms over the past 6 months: nocturia ≥2 voids/night, daytime frequency >8×day, urgency
  • Body mass index (BMI) ≤40 kg/m2
  • Willing to use a rectally administered product once daily for 12 weeks

Exclusion criteria

  • Male subject has history of bacterial prostatitis or benign prostatic hyperplasia with active symptoms that are difficult to distinguish from IC/BPS
  • Has a condition that can be a contraindication to using a rectal foam
  • Has cancer under active treatment or a history of uterine, cervical, pelvic, colorectal, ovarian, or vaginal cancer
  • Has a history of benign or malignant bladder tumors
  • Has an active urinary tract infection or had ≥2 UTIs within the past 90 days
  • Has an uncontrolled major psychiatric condition or has made a suicide attempt during the past 2 years
  • Has a malabsorption syndrome
  • Had surgery in the pelvic or abdominal region within the past 90 days or is planning pelvic or abdominal region surgical procedures before the end of the study
  • Has received a cystoscopy with or without hydrodistension for diagnostic purposes (ie, not for pain relief) within the past 30 days or a cystoscopy with therapeutic hydrodistension (ie, for pain relief) within the past 90 days or is planning a cystoscopy for any reason before the end of the study
  • Has history of pelvic irradiation or radiation cystitis, or drug-induced cystitis.
  • Has a recent history of drug or alcohol abuse

Trial design

Primary purpose




Interventional model

Parallel Assignment


Double Blind

300 participants in 3 patient groups, including a placebo group

IW-3300 100 µg
Experimental group
IW-3300 at 100 µg rectal foam administered daily for 12 weeks
Drug: IW-3300 rectal foam
IW-3300 300 µg
Experimental group
IW-3300 at 300 µg rectal foam administered daily for 12 weeks
Drug: IW-3300 rectal foam
Placebo Comparator group
Placebo rectal foam administered daily for 12 weeks
Drug: Placebo

Trial contacts and locations



Central trial contact

Study Manager

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems